A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines
A Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines
This is a multicenter, randomized, double-blind, active-controlled Phase III clinical study to evaluate the safety and efficacy of LP-003 injection in patients with chronic spontaneous urticaria who remain symptomatic despite treatment with H1 antihistamines.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Jie Yang
- 电话号码:+8621-58372390
- 邮箱:yangj@longbiopharma.com
学习地点
-
-
-
Beijing、中国
- Peking Union Medical College Hospital
-
接触:
- Yuxiang Zhi
- 电话号码:+8610-69151188
- 邮箱:yuxiang_zhi@126.com
-
Shenyang、中国
- The First Affiliated Hospital of China Medical University
-
接触:
- Xinghua Gao
- 电话号码:+8624-83282524
- 邮箱:Gaobarry@hotmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Have the capacity to understand the study and voluntarily signs the informed consent form (ICF);
- Male or female participant must be 12 to 75 years old at the time of ICF signature;
- Duration of chronic spontaneous urticaria (CSU) ≥ 6 months prior to screening;
- Presence of pruritus and wheals for at least 6 consecutive weeks before screening despite treatment with H1-AH;
- Participants have been on a stable dose of second-generation H1-AH as specified in the protocol for ≥2 weeks prior to randomization and within the 7 days before randomization, the UAS7( range 0-42) ≥16 and ISS7(range 0-21) ≥8;
- Participants must not miss UAS scores for more than one day within the 7 days prior to randomization, and are willing and able to complete daily symptom diaries during the study period.
- Female participants of childbearing potential, and male participants (and their female partners), must use one or more effective contraceptive measures from the screening period until at least 6 months after the last administration of investigational product. Participants must have no plans for pregnancy, sperm donation or oocyte donation from screening until at least 6 months after the last dose of investigational product.
Exclusion Criteria:
- The subject has a primary or sole trigger for chronic urticaria (chronic Induced urticaria), including artificial urticaria (Symptomatic Dermographism), cold, heat, sun, pressure, delayed pressure, water, cholinergic, or contact urticaria;
- Other medical conditions accompanied by symptoms of urticaria or angioedema including, but not limited to, urticarial vasculitis, mastocytosis, pigmented urticaria, erythema multiforme, , hereditary or acquired angioedema, etc;
- Any other dermatologic condition with chronic itching, such as atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis, which in the judgment of the Investigator may affect the evaluation of the study and the results of the study;
- Body weight < 40 kg
- Not enough washing-out period for previous therapy before randomization.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:LP-003 group
Participants received LP-003 subcutaneously during the 48-week treatment period |
s.c. injection |
|
有源比较器:Omalizumab group
Participants received omalizumab subcutaneously during the 48-week treatment period |
s.c. injection |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in weekly Urticaria Activity Score (UAS7) at week 12
大体时间:Week 12
|
The UAS7 is a composite score derived from the ISS7 and the HSS7, i.e., the sum of ISS7 and HSS7, ranging from 0 to 42 points. UAS7 = 0 indicates complete resolution of urticaria. |
Week 12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from baseline in UAS7 at each assessment visit (excluding Week 12)
大体时间:up to approximately 56 weeks
|
up to approximately 56 weeks
|
|
|
The proportion of participants with UAS7 = 0 at each assessment visit
大体时间:up to approximately 56 weeks
|
up to approximately 56 weeks
|
|
|
The proportion of participants with UAS7 ≤ 6at each assessment visit
大体时间:up to approximately 56 weeks
|
up to approximately 56 weeks
|
|
|
Change From Baseline in weekly hives severity score (HSS7) at each assessment visit.
大体时间:up to approximately 56 weeks
|
The HSS7 is the sum of daily HSS scores over the 7 days prior to the visit, ranging from 0 to 21 points. HSS7 = 0 indicates complete resolution of hives. |
up to approximately 56 weeks
|
|
Change From Baseline in weekly itch severity score ( ISS7) at each assessment visit.
大体时间:Time Frame: up to approximately 56 weeks
|
The ISS7 is the sum of daily ISS scores over the 7 days prior to the visit, ranging from 0 to 21 points. ISS7 = 0 indicates complete resolution of itch. |
Time Frame: up to approximately 56 weeks
|
|
Change From Baseline in weekly angloedema activity score (AAS7) at each assessment visit.
大体时间:Time Frame: up to approximately 56 weeks
|
The AAS7 is the sum of the daily AAS scores over the 7 days prior to the visit, ranging from 0 to 105 points. AAS7 = 0 indicates no angioedema. |
Time Frame: up to approximately 56 weeks
|
|
Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at each assessment visit
大体时间:up to approximately 56 weeks
|
The scale consists of 23 items. Each item is scored from 1 to 5 points. The total score is transformed to a scale ranging from 0 to 100, with higher scores indicating a greater impact of the disease on patients' quality of life |
up to approximately 56 weeks
|
|
The incidence of adverse events during the study
大体时间:up to approximately 56 weeks
|
Incidence and severity of AE from first dose to end of study are recorded |
up to approximately 56 weeks
|
合作者和调查者
调查人员
- 首席研究员:Xinghua Gao、First Hospital of China Medical University
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.